MOTS-C Research Study: Reading a Hemodialysis Cohort Association

A MOTS-C research study can report a biomarker association without testing MOTS-C as an intervention. This article reads the multicenter cohort reported by Bolignano and colleagues (PMID 39111290; DOI 10.1159/000540303). The study followed prevalent chronic hemodialysis patients, measured circulating MOTS-c, and examined whether that measurement added information to mortality and cardiovascular risk models. Its evidence is observational and cohort-specific. It does not administer MOTS-c, test a research-material lot, or establish a treatment effect.

Define the cohort before interpreting the marker

The reported cohort contained 94 prevalent hemodialysis patients and used a prospective, observational, multicenter design. Median follow-up was 26.5 months. The composite endpoint combined all-cause mortality with non-fatal cardiovascular events, and 53 participants experienced that endpoint during follow-up. These numbers define the population and denominator for the paper’s association and prediction analyses. They should not be silently generalized to people who are not receiving chronic hemodialysis.

The accessible abstract does not provide a complete sampling schedule, the relationship between blood collection and a dialysis session, the assay platform, or the exact number of participating centers. Those are material study fields. A reviewer should retrieve them from the full article if they are needed and should leave them marked as unreported when the accessible record does not supply them.

What was measured and compared

The authors measured circulating MOTS-c and compared models built from cohort-related risk factors with models that also included MOTS-c. The abstract names age, left-ventricular mass, evidence of diastolic dysfunction, diabetes, and pulse pressure among the predictors. The design asks whether a measured marker changes model performance in this cohort. It does not ask whether changing a person’s MOTS-c concentration changes a later event.

The study also compared MOTS-c levels between hemodialysis patients and controls. The abstract reports higher levels in the hemodialysis group (p < 0.001), and higher levels among the 53 participants who experienced the composite endpoint (p = 0.01). These are group-level findings under the paper’s selection, measurement, and follow-up conditions. They are not a diagnostic cutoff, a personal prognosis, or evidence that MOTS-c is the cause of an outcome.

Read the two regression estimates in context

The paper used multivariable logistic regression and Cox regression to examine association with the composite endpoint. In the abstract, MOTS-c was independently associated with the endpoint with an odds ratio of 1.020 (95% CI 1.011 to 1.109; p = 0.03) in the logistic analysis and a hazard ratio of 1.004 (95% CI 1.000 to 1.025; p = 0.05) in the Cox analysis.

An odds ratio and a hazard ratio answer different statistical questions. The first is tied to the logistic model’s outcome framing; the second incorporates time-to-event information. They are not two independent clinical effects and should not be averaged, added, or translated into a treatment response. The confidence intervals and p-values belong to the specified cohort and model specification.

Understand what the model metrics mean

Adding MOTS-c to the stated risk-predictor models changed several reported metrics. Receiver-operating-characteristic area under the curve moved from 0.727 to 0.743. The C-index moved from 0.658 to 0.700. Net reclassification improvement was reported as 15.87% (p = 0.01). These values describe an apparent model-comparison result in a 94-patient cohort. They do not validate a general-purpose test, establish calibration in a new population, or show that a clinician using the marker improves outcomes.

Prediction performance also depends on event count, variable selection, missing-data handling, model optimism, and external validation. The abstract does not establish that the reported metrics were reproduced in an independent cohort. A careful record therefore says that MOTS-c changed the specified metrics in the published analysis, while leaving transportability and prospective validation as open questions.

Separate association from causation

Observational adjustment can account for measured covariates, but it cannot guarantee that all relevant confounding has been removed. Dialysis vintage, inflammation, nutritional status, comorbid disease, medication exposure, and timing of blood collection could matter if they were unevenly distributed or incompletely measured. The abstract alone cannot determine whether MOTS-c itself, a dialysis-related process, an unmeasured characteristic, or a combination explains the observed association.

The defensible conclusion is narrow: in this reported chronic hemodialysis cohort, circulating MOTS-c was associated with a composite mortality and cardiovascular endpoint, and adding the marker altered the stated prediction metrics. The paper does not show that MOTS-c caused, prevented, or treated the endpoint. It also does not establish a target concentration or a response threshold.

Time, exposure, and missing intervention fields

The 26.5-month median follow-up is a cohort observation window, not a dosing period. The paper does not report a MOTS-c intervention, route, administered amount, treatment response, or product lot. It therefore cannot answer questions about administration, repeated exposure, pharmacokinetics, safety, or efficacy. Those fields are outside this source record and must not be filled by analogy from another peptide study.

Likewise, a measured circulating level is not automatically equivalent to a tissue level or a concentration in a supplied vial. A product record and a cohort biomarker record have different experimental units. Keeping them separate prevents a biomarker association from being misread as a specification or a use recommendation.

Use both source records without double-counting evidence

PubMed provides the bibliographic record for the article, including the cohort-study title, journal, PMID, and DOI. The DOI landing record provides a second direct route to the publisher’s article record. These two URLs improve traceability, but they point to the same study and do not represent two independent cohorts. Claims about the 94 participants, 53 events, follow-up, regression estimates, and model metrics remain claims from one paper.

When reviewing the full article, verify the sample-collection timing, assay method, missing-data rules, covariate definitions, event adjudication, and any internal or external validation. If a detail is absent from the accessible source, record it as unknown rather than importing values from another MOTS-C publication.

Difference from related Peptides Bio records

This page targets the exact query mots c research study by reading one human hemodialysis cohort and its predictive-marker analysis. It is distinct from the MOTS-C overview, the evidence-by-model classification, the 12S rRNA origin record, and the HEK293 nuclear-localisation study. Those pages address broader identity, model classification, molecular origin, or cell-model evidence; none supplies this paper’s 94-patient denominator, 26.5-month follow-up, 53 composite events, adjusted estimates, and model-metric comparison.

The related MOTS-C 20 mg research material page is a catalogue record. It does not prove that the material was used in the cohort or that its documentation matches the circulating biomarker measured in the paper.

References and scope

• Bolignano D, Greco M, Presta P, Duni A, Zicarelli M, Mercuri S, Pappas E, Lakkas L, Musolino M, Naka KK, Misiti R, Foti DP, Andreucci M, Coppolino G, Dounousi E. The Mitochondrial-Derived Peptide MOTS-c May Refine Mortality and Cardiovascular Risk Prediction in Chronic Hemodialysis Patients: A Multicenter Cohort Study. Blood Purification. 2024;53(10):824-837. PMID 39111290. DOI: 10.1159/000540303.
• Publisher DOI record for Bolignano et al., Blood Purification 2024;53(10):824-837. DOI: 10.1159/000540303.

Research scope: This summary reports study details from the cited records and does not provide medical, veterinary, dosing, administration, safety, or treatment guidance. It does not represent a product-use recommendation.